These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 19709880)

  • 61. Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase.
    Wang Z; Vince R
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1293-6. PubMed ID: 18226894
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Non-nucleoside HIV-1 reverse-transcriptase inhibitors. Part 10. Synthesis and anti-HIV activity of 5-alkyl-6-(1-naphthylmethyl)pyrimidin-4(3H)-ones with a mono- or disubstituted 2-amino function as novel 'dihydro-alkoxy-benzyl-oxopyrimidine' (DABO) analogues.
    Wang Y; Chen FE; Balzarini J; De Clercq E; Pannecouque C
    Chem Biodivers; 2008 Jan; 5(1):168-76. PubMed ID: 18205120
    [TBL] [Abstract][Full Text] [Related]  

  • 63. 1,2,3-Selenadiazole thioacetanilides: synthesis and anti-HIV activity evaluation.
    Zhan P; Liu X; Fang Z; Pannecouque C; De Clercq E
    Bioorg Med Chem; 2009 Sep; 17(17):6374-9. PubMed ID: 19647440
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
    Meng G; Liu Y; Zheng A; Chen F; Chen W; De Clercq E; Pannecouque C; Balzarini J
    Eur J Med Chem; 2014 Jul; 82():600-11. PubMed ID: 24952305
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.
    Ribone SR; Leen V; Madrid M; Dehaen W; Daelemans D; Pannecouque C; Briñón MC
    Eur J Med Chem; 2012 Dec; 58():485-92. PubMed ID: 23159806
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
    Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
    J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.
    O'Meara JA; Yoakim C; Bonneau PR; Bös M; Cordingley MG; Déziel R; Doyon L; Duan J; Garneau M; Guse I; Landry S; Malenfant E; Naud J; Ogilvie WW; Thavonekham B; Simoneau B
    J Med Chem; 2005 Aug; 48(17):5580-8. PubMed ID: 16107158
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents.
    Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E
    Bioorg Med Chem; 2007 May; 15(9):3134-42. PubMed ID: 17349793
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Chen X; Zhan P; Pannecouque C; Balzarini J; De Clercq E; Liu X
    Eur J Med Chem; 2012 May; 51():60-6. PubMed ID: 22405288
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
    Le Van K; Cauvin C; de Walque S; Georges B; Boland S; Martinelli V; Demonté D; Durant F; Hevesi L; Van Lint C
    J Med Chem; 2009 Jun; 52(12):3636-43. PubMed ID: 19469474
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
    Shi J; McAtee JJ; Schlueter Wirtz S; Tharnish P; Juodawlkis A; Liotta DC; Schinazi RF
    J Med Chem; 1999 Mar; 42(5):859-67. PubMed ID: 10072683
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase.
    Gomez R; Jolly SJ; Williams T; Vacca JP; Torrent M; McGaughey G; Lai MT; Felock P; Munshi V; Distefano D; Flynn J; Miller M; Yan Y; Reid J; Sanchez R; Liang Y; Paton B; Wan BL; Anthony N
    J Med Chem; 2011 Nov; 54(22):7920-33. PubMed ID: 21985673
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor.
    Li Z; Han J; Chen HF
    Chem Biol Drug Des; 2008 Nov; 72(5):350-9. PubMed ID: 19012571
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Murugesan V; Tiwari VS; Saxena R; Tripathi R; Paranjape R; Kulkarni S; Makwana N; Suryawanshi R; Katti SB
    Bioorg Med Chem; 2011 Nov; 19(22):6919-26. PubMed ID: 21982685
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Investigation of novel lipid-functionalized PNA monomers as potential HIV-1 non-nucleoside reverse transcriptase and/or integrase inhibitors.
    Thomas MG; Maga G; Mouscadet JF; Howarth NM
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1063-6. PubMed ID: 18058537
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Sweeney ZK; Dunn JP; Li Y; Heilek G; Dunten P; Elworthy TR; Han X; Harris SF; Hirschfeld DR; Hogg JH; Huber W; Kaiser AC; Kertesz DJ; Kim W; Mirzadegan T; Roepel MG; Saito YD; Silva TM; Swallow S; Tracy JL; Villasenor A; Vora H; Zhou AS; Klumpp K
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4352-4. PubMed ID: 18632268
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Das K; Lewi PJ; Hughes SH; Arnold E
    Prog Biophys Mol Biol; 2005 Jun; 88(2):209-31. PubMed ID: 15572156
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Synthesis and biological evaluation of novel 2-arylalkylthio-4-amino-6-benzyl pyrimidines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Qin H; Liu C; Zhang J; Guo Y; Zhang S; Zhang Z; Wang X; Zhang L; Liu J
    Bioorg Med Chem Lett; 2010 May; 20(9):3003-5. PubMed ID: 20347295
    [TBL] [Abstract][Full Text] [Related]  

  • 79. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
    Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
    J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nitroimidazoles. V. Synthesis and anti-HIV evaluation of new 5-substituted piperazinyl-4-nitroimidazole derivatives.
    Al-Soud YA; Al-Masoudi NA; Hassan HG; De Clercq E; Pannecouque C
    Acta Pharm; 2007 Dec; 57(4):379-93. PubMed ID: 18165184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.